Juno Therapeutics (+2% at 15-month high) followup: Celgene (CELG) is the rumored suitor... (46.31 +0.99)
Celgene owns 9.7% of the company after partnering with Juno in June of 2015. Gilead's acquisition of JUNO peer Kite (KITE) has recently brought the CAR-T space back into focus.